Comparison study of gastrinomas between gastric and non-gastric origins

World Journal of Surgical Oncology

Ming-Chin Yu²  Tsann-Long Hwang²  Chun-Jung Lin⁴  Tse-Ching Chen³  Kuang-Tse Pan¹  Chao-Wei Lee²  I-Ming Kuo²  Song-Fong Huang² 

[1] Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, 5, Fu-Shin Street, Kweishan 333, Taoyuan, Taiwan;Department of Surgery, Chang Gung Memorial Hospital, 5, Fu-Shin Street, Kweishan 333, Taoyuan, Taiwan;Department of Pathology, Chang Gung Memorial Hospital, 5, Fu-Shin Street, Kweishan 333, Taoyuan, Taiwan;Department of General Gastroenterology, Chang Gung Memorial Hospital, 5, Fu-Shin Street, Kweishan 333, Taoyuan, Taiwan

关键词: Prognosis;    Liver metastasis;    Lymph node metastasis;    Gastrinoma;   

Others  :  1218714
DOI  :  10.1186/s12957-015-0614-6

 received in 2015-02-10, accepted in 2015-05-28,  发布年份 2015

【 摘 要 】

Background

Gastrinomas are one of the neuroendocrine tumors with potential distant metastasis. Most gastrinomas are originated from pancreas and duodenum, but those of gastric origin have been much less reported. The aim of the study is to compare gastrinomas of gastric and non-gastric origins.

Methods

Four hundred twenty-four patients with neuroendocrine tumor by histological proof in Chang Gung Memorial Hospital, Linkou branch in the past 10 years were included. A total of 109 (25.7 %) cases were identified of upper gastrointestinal origins, of which 20 (18.3 %) were proven gastrinomas. The clinical characteristics were collected and analyzed retrospectively.

Results

In our study, 21 tumors of the 20 cases were identified by pathologic proof, 11 (55 %) had resection or endoscopic mucosa resection, 9 of gastric origins, 9 of duodenal origins, 2 of pancreatic origins, and 1 of hepatic origins. One case had multiple lesions. Patients with gastric gastrinomas had older age, higher levels of gastrin, seemingly smaller tumor size (p = 0.024, 0.030, and 0.065, respectively), and usually lower grade in differentiation (p = 0.035). Though gastric gastrinomas had a high recurrent rate (80 %), the lymph node and liver involvement was less common. Gastrinomas with liver involvement/metastasis had a high mortality rate where 80 % died of liver dysfunction.

Conclusions

Gastrinomas originating from stomach had higher gastrin level and lower tumor grading and presented at older age. The long-term outcome was probably better than non-gastric origin because of lower grading and less lymph node and liver involvement.

【 授权许可】

   
2015 Huang et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012; 26(6):691-703.
• [2]Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV et al.. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008; 9(1):61-72.
• [3]Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al.. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72.
• [4]Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors. Endocrinol Metab Clin North Am. 2011; 40(1):1-18.
• [5]Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V et al.. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010; 21(9):1794-803.
• [6]Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013; 24(12):3040-4.
• [7]Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K et al.. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015; 50(1):58-64.
• [8]Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014; 21(3):R153-63.
• [9]Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL et al.. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine. 2000; 79(6):379-411.
• [10]Epelboym I, Mazeh H. Zollinger-Ellison syndrome: classical considerations and current controversies. Oncologist. 2014; 19(1):44-50.
• [11]Roy PK, Venzon DJ, Feigenbaum KM, Koviack PD, Bashir S, Ojeaburu JV et al.. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine. 2001; 80(3):189-222.
• [12]Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine. 2004; 83(1):43-83.
• [13]Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955; 142(4):709-23.
• [14]Zogakis TG, Gibril F, Libutti SK, Norton JA, White DE, Jensen RT et al.. Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg. 2003; 238(1):42-8.
• [15]Cisco RM, Norton JA. Surgery for gastrinoma. Adv Surg. 2007; 41:165-76.
• [16]Stabile BE, Morrow DJ, Passaro E. The gastrinoma triangle: operative implications. Am J Surg. 1984; 147(1):25-31.
• [17]O’Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012; 26(6):719-35.
• [18]Krampitz GW, Norton JA. Current management of the Zollinger-Ellison syndrome. Adv Surg. 2013; 47:59-79.
• [19]Giovinazzo F, Butturini G, Monsellato D, Malleo G, Marchegiani G, Bassi C. Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. Updates Surg. 2013; 65(1):19-24.
• [20]Veenendaal LM et al.. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol. 2006; 4:35. BioMed Central Full Text
• [21]Maire F, Sauvanet A, Couvelard A, Rebours V, Vullierme MP, Lebtahi R et al.. Recurrence after surgical resection of gastrinoma: who, when, where and why? Eur J Gastroenterol Hepatol. 2012; 24(4):368-74.
• [22]Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014; 39(10):1071-84.
• [23]Li QL, Zhang YQ, Chen WF, Xu MD, Zhong YS, Ma LL et al.. Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol. 2012; 18(40):5799-806.
• [24]Crosby DA, Donohoe CL, Fitzgerald L, Muldoon C, Hayes B, O'Toole D et al.. Gastric neuroendocrine tumours. Dig Surg. 2012; 29(4):331-48.
• [25]Bosman F, Carneiro F, Hruban RH, Theise N. WHO classification of tumours of the digestive system. IARC Press, Lyons; 2010.
• [26]Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine. 2006; 85(6):295-330.
• [27]Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB et al.. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995; 108(6):1637-49.
• [28]Donow C, Pipeleers-Marichal M, Schroder S, Stamm B, Heitz PU, Kloppel G. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer. 1991; 68(6):1329-34.
• [29]Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004; 99(1):23-32.
• [30]Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A et al.. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002; 94(2):331-43.
• [31]Bartsch DK, Waldmann J, Fendrich V, Boninsegna L, Lopez CL, Partelli S et al.. Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg. 2012; 99(9):1234-40.
• [32]Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014:13-27.